Volatile Biotech Stocks: Geron Corporation (NASDAQ:GERN), Opexa Therapeutics Inc (NASDAQ:OPXA), RNA, CytRx Corporation (NASDAQ:CYTR)

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) shares after opening at $1.80 on last trade day and at the end of the day closed at $2.48. Company price to sales ratio in past twelve months was calculated as 187.16 and price to cash ratio as 4.81. Geron Corporation (NASDAQ:GERN) showed a negative weekly performance of -43.64%.

Opexa Therapeutics Inc (NASDAQ:OPXA), reported financial results for the year ended December 31, 2013, and provided an overview of recent corporate developments. Reported cash and cash equivalents of $23,644,542 as of December 31, 2013; Closed two underwritten public offerings of an aggregate of 17,638,000 shares of common stock during the second half of 2013 for aggregate gross proceeds of approximately $27.4 million, or net proceeds of approximately $24.8 million after deducting underwriting discounts and commissions and offering expenses; Eliminated debt on Opexa’s consolidated balance sheet through the conversion into common stock of the July 2012 convertible secured promissory notes in an aggregate principal amount of $4.1 million, and unencumbered all of our intellectual property and physical assets previously pledged as collateral; Strengthened the team with the addition of several talented individuals dedicated to furthering the Company’s development initiatives, including enhancing the manufacturing and delivery of Tcelna; Opexa Therapeutics Inc (NASDAQ:OPXA) shares advanced 14.81% in last trading session and ended the day on $2.17. OPXA return on equity ratio is recorded as -239.40% and its return on assets is -127.90%. Opexa Therapeutics Inc (NASDAQ:OPXA) yearly performance is 4.83%.

Shares of drugmaker Prosensa Holding NV (NASDAQ:RNA) reported 48-week data from its Phase II placebo-controlled study of its lead compound, drisapersen, for the treatment of Duchenne Muscular Dystrophy, or DMD. The results indicate that, compared to placebo, boys in the higher-dose drisapersen group experienced stabilization and even improvements in their muscle function and physical activity as measured by the six-minute walk test for the 24-week treatment phase and maintained this improvement during the 24-week follow-up period, Prosensa stated. Another company developing its own treatment for DMD, Sarepta Therapeutics (SRPT), is up about 2% to $27.99 in pre-market trading following Prosensa’s report. Prosensa Holding NV (NASDAQ:RNA) shares moved up 3.85% in last trading session and was closed at $7.02, while trading in range of $6.92 – $8.80. Prosensa Holding NV (NASDAQ:RNA) year to date (YTD) performance is 50.32%.

Zeldes Haeggquist & Eck, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into possible violations of the federal securities laws and other violations at CytRx Corporation (NASDAQ:CYTR).CytRx Corporation (NASDAQ:CYTR) weekly performance is -17.74%. On last trading day company shares ended up $4.08. CytRx Corporation (NASDAQ:CYTR) distance from 50-day simple moving average (SMA50) is -35.60%. Analysts mean target price for the company is $11.00.